
Assembly Biosciences, Inc. (NASDAQ:ASMB – Free Report) – Analysts at HC Wainwright cut their FY2026 earnings estimates for shares of Assembly Biosciences in a note issued to investors on Tuesday, November 17th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings of $1.36 per share for the year, down from their previous forecast of $2.28. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is $2.28 per share. HC Wainwright also issued estimates for Assembly Biosciences’ Q4 2026 earnings at $2.75 EPS, Q1 2027 earnings at ($0.25) EPS, Q2 2027 earnings at ($0.98) EPS, Q3 2027 earnings at ($0.96) EPS, Q4 2027 earnings at $1.43 EPS, FY2027 earnings at ($0.71) EPS, FY2028 earnings at $0.49 EPS, FY2029 earnings at ($2.21) EPS and FY2030 earnings at $3.07 EPS.
Assembly Biosciences (NASDAQ:ASMB – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.27). Assembly Biosciences had a negative net margin of 16.57% and a negative return on equity of 4.40%. The company had revenue of $2.96 million during the quarter, compared to the consensus estimate of $9.07 million.
A number of other brokerages have also recently weighed in on ASMB. Zacks Research cut shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 9th. UBS Group decreased their price target on shares of Assembly Biosciences from $52.00 to $48.00 and set a “buy” rating for the company in a report on Tuesday, November 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Thursday, October 15th. Finally, Mizuho set a $53.00 price objective on Assembly Biosciences in a research note on Tuesday, September 1st. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $46.50.
Read Our Latest Stock Analysis on Assembly Biosciences
Assembly Biosciences Stock Performance
Shares of NASDAQ ASMB opened at $22.39 on Thursday. Assembly Biosciences has a 52-week low of $19.20 and a 52-week high of $39.71. The stock has a market cap of $458.55 million, a P/E ratio of 27.64 and a beta of 1.26. The firm has a 50 day moving average price of $22.48 and a 200 day moving average price of $26.78.
Hedge Funds Weigh In On Assembly Biosciences
Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its holdings in shares of Assembly Biosciences by 113.3% in the first quarter. Bank of America Corp DE now owns 10,902 shares of the biopharmaceutical company’s stock valued at $303,000 after purchasing an additional 5,792 shares in the last quarter. Algert Global LLC acquired a new position in shares of Assembly Biosciences during the third quarter worth about $272,000. Renaissance Technologies LLC boosted its position in shares of Assembly Biosciences by 69.4% during the first quarter. Renaissance Technologies LLC now owns 15,651 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 6,411 shares during the period. Engineers Gate Manager LP grew its holdings in shares of Assembly Biosciences by 88.5% during the second quarter. Engineers Gate Manager LP now owns 17,766 shares of the biopharmaceutical company’s stock worth $488,000 after buying an additional 8,343 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Assembly Biosciences during the second quarter worth about $660,000. Institutional investors own 19.92% of the company’s stock.
Insider Buying and Selling at Assembly Biosciences
In other news, insider Anuj Gaggar sold 2,593 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $19.62, for a total value of $50,874.66. Following the completion of the transaction, the insider owned 53,800 shares in the company, valued at $1,055,556. This represents a 4.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jason Okazaki sold 6,202 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $19.62, for a total transaction of $121,683.24. Following the completion of the transaction, the chief executive officer owned 195,532 shares of the company’s stock, valued at $3,836,337.84. This trade represents a 3.07% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 12,115 shares of company stock valued at $237,696. 3.50% of the stock is currently owned by corporate insiders.
Trending Headlines about Assembly Biosciences
Here are a few of the latest headlines about ASMB:
- Positive Sentiment: HC Wainwright maintained its Buy rating and $50 price target, offering a bullish counterpoint to its reduced forecasts. MarketBeat ASMB coverage
- Neutral Sentiment: Assembly Biosciences appeared at the UBS Global Biopharma Conference; the provided transcript listing does not include specific new company updates. UBS conference transcript
- Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to $1.36 from $2.28 and its FY2027 forecast to a loss of $0.71 per share from earnings of $0.05. It also reduced estimates for FY2028 ($0.49 from $0.84), Q4 2026 ($2.75 from $3.19), and multiple 2027 quarters—including changing Q1 from a $0.02 profit to a $0.25 loss. These broad downward revisions may weigh on investor expectations, despite a slight improvement in its FY2029 loss estimate. MarketBeat ASMB coverage
Assembly Biosciences Company Profile
Assembly Biosciences is a clinical-stage biotechnology company focused on developing oral antiviral therapies for viral infections. Its research programs target hepatitis B virus (HBV) and herpesviruses, including herpes simplex virus. The company’s pipeline includes investigational antiviral candidates designed to interfere with key steps in viral replication. Assembly has also worked with Gilead Sciences on antiviral development, including programs targeting herpesviruses. Its therapies remain under investigation and are not approved medicines.
Further Reading
- Five stocks we like better than Assembly Biosciences
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
